- Home
- NFE vs LYEL Comparison
NFE vs LYEL Comparison
Compare NFE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFE | LYEL |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 490.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NFE | LYEL |
|---|---|---|
| Price | $1.06 | $26.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $7.70 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 5.5M | 91.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,364,860,000.00 | $61,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.98 | $0.39 |
| 52 Week High | $12.59 | $45.00 |
Technical Indicators
Market Signals| Indicator | NFE | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 56.63 |
| Support Level | $1.03 | $21.27 |
| Resistance Level | $1.40 | $27.30 |
| Average True Range (ATR) | 0.09 | 1.76 |
| MACD | -0.01 | 0.34 |
| Stochastic Oscillator | 2.86 | 77.04 |
Price Performance
Historical ComparisonAbout NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.